Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Leases (2019 - 2025)

Harvard Bioscience (HBIO) has disclosed Current Leases for 7 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases changed N/A to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a N/A change, with the full-year FY2024 number at $1.2 million, down 18.22% from a year prior.
  • Current Leases was $1.5 million for Q3 2025 at Harvard Bioscience, up from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.2 million in Q1 2022 to a low of $1.2 million in Q4 2024.
  • A 5-year average of $1.9 million and a median of $2.1 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: increased 4.42% in 2022, then tumbled 43.8% in 2024.
  • Harvard Bioscience's Current Leases stood at $2.1 million in 2021, then fell by 0.33% to $2.1 million in 2022, then crashed by 33.68% to $1.4 million in 2023, then fell by 18.22% to $1.2 million in 2024, then increased by 28.32% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Current Leases are $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $1.2 million (Q4 2024).